Table 3

Treatment completion classified by patient characteristics across countries*

India (Punjab State only)IndonesiaMyanmarNigeria (Nasarawa State only)Vietnam
% completed
treatment
%completed
treatment
% completed treatment% completed
treatment
% completed treatment
N79 894/87 5225785/72972003/2033120/1391749/1866
Total %91.379.398.586.393.7
Sex
 Female96.078.598.785.594.6
 Male89.279.998.487.393.6
 Transgender88.2
 Unknown0.0
Age
 12–1983.585.7100.0†100.0†
 20–2986.476.297.5100.0†91.7
 30–3991.784.298.983.393.9
 40–4994.880.898.683.393.9
 50–5994.576.499.190.294.3
 60–6993.174.697.180.092.4
 70+90.072.499.383.393.2
 Missing91.176.9100.0†
Family history of HCV
 Yes84.199.5100.0†
 None reported91.398.486.2
History of injecting drugs
 Yes76.888.499.693.8
 None reported92.076.898.486.393.7
Known HIV coinfection
 Yes75.384.798.8100.0†94.8
 No91.677.798.486.093.2
Known HBV coinfection
 Yes33.3†100.0100.093.1
 No91.398.585.393.8
Cirrhosis
 Compensated89.8%98.3%92.1%
 Decompensated79.5%99.4%93.2%
 Cirrhotic (no additional information)88.4%69.6%100.0%†
 Non-cirrhotic91.7%85.2%98.5%85.6%94.8%
 Missing50%†
Treatment regimen
 SOF/DCV91.6%78.9%98.5%86.3%94.1%
 SOF/DCV+RBV64.2%90.4%93.1%
 SOF/VEL89.8%
 SOF/VEL+RBV90.3%
 Other85.2%80.0%
Treatment duration
 12 weeks91.885.599.385.693.9%
 24 weeks86.568.996.9100.0†91.8%
 Other97.2100.0%†
Year of treatment initiation
 201697.10.0†
 201794.082.898.7100.095.8
 201892.386.097.791.792.4
 201986.984.679.4100.0†
 202083.676.9
 202180.166.2
 20220.0
  • *Patients who died were excluded from this analysis, as the data did not consistently indicate the timing of death (pretreatment or post-treatment completion).

  • †Sample size was <10 people in this category.

  • DCV, daclatasvir; HBV, hepatitis B virus; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.